JP2015501845A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501845A5
JP2015501845A5 JP2014547462A JP2014547462A JP2015501845A5 JP 2015501845 A5 JP2015501845 A5 JP 2015501845A5 JP 2014547462 A JP2014547462 A JP 2014547462A JP 2014547462 A JP2014547462 A JP 2014547462A JP 2015501845 A5 JP2015501845 A5 JP 2015501845A5
Authority
JP
Japan
Prior art keywords
alkyl
group
independently
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501845A (ja
JP6300730B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/069637 external-priority patent/WO2013090664A1/en
Publication of JP2015501845A publication Critical patent/JP2015501845A/ja
Publication of JP2015501845A5 publication Critical patent/JP2015501845A5/ja
Application granted granted Critical
Publication of JP6300730B2 publication Critical patent/JP6300730B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547462A 2011-12-16 2012-12-14 ベツリンの誘導体 Expired - Fee Related JP6300730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576448P 2011-12-16 2011-12-16
US61/576,448 2011-12-16
PCT/US2012/069637 WO2013090664A1 (en) 2011-12-16 2012-12-14 Derivatives of betulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018000027A Division JP2018065867A (ja) 2011-12-16 2018-01-04 ベツリンの誘導体

Publications (3)

Publication Number Publication Date
JP2015501845A JP2015501845A (ja) 2015-01-19
JP2015501845A5 true JP2015501845A5 (enExample) 2016-01-28
JP6300730B2 JP6300730B2 (ja) 2018-03-28

Family

ID=48613199

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014547462A Expired - Fee Related JP6300730B2 (ja) 2011-12-16 2012-12-14 ベツリンの誘導体
JP2018000027A Withdrawn JP2018065867A (ja) 2011-12-16 2018-01-04 ベツリンの誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018000027A Withdrawn JP2018065867A (ja) 2011-12-16 2018-01-04 ベツリンの誘導体

Country Status (38)

Country Link
US (6) US20150218142A1 (enExample)
EP (2) EP3263580A1 (enExample)
JP (2) JP6300730B2 (enExample)
KR (1) KR101953869B1 (enExample)
CN (2) CN107501383A (enExample)
AR (1) AR089285A1 (enExample)
AU (1) AU2012352110B2 (enExample)
BR (1) BR112014014769A2 (enExample)
CA (1) CA2859030C (enExample)
CL (1) CL2014001585A1 (enExample)
CO (1) CO6970600A2 (enExample)
CR (1) CR20140301A (enExample)
CY (1) CY1119422T1 (enExample)
DK (1) DK2791103T3 (enExample)
DO (1) DOP2014000121A (enExample)
EA (2) EA201790923A1 (enExample)
ES (1) ES2644578T3 (enExample)
HR (1) HRP20171512T1 (enExample)
HU (1) HUE034877T2 (enExample)
IL (1) IL233081A (enExample)
JO (1) JO3387B1 (enExample)
LT (1) LT2791103T (enExample)
MA (1) MA35833B1 (enExample)
ME (1) ME02895B (enExample)
MX (1) MX360679B (enExample)
PE (1) PE20141788A1 (enExample)
PH (3) PH12014501362A1 (enExample)
PL (1) PL2791103T3 (enExample)
PT (1) PT2791103T (enExample)
RS (1) RS56373B1 (enExample)
SG (1) SG11201402707PA (enExample)
SI (1) SI2791103T1 (enExample)
SM (1) SMT201700466T1 (enExample)
TW (2) TWI583696B (enExample)
UA (1) UA116978C2 (enExample)
UY (1) UY34523A (enExample)
WO (1) WO2013090664A1 (enExample)
ZA (1) ZA201404135B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN103242413B (zh) * 2012-02-08 2015-08-26 江西青峰药业有限公司 Lupane三萜系衍生物及其药学用途
SG11201503807TA (en) * 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
BR112017009853A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, uso de uma quantidade melhoradora de hiv de um composto
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
KR20180028535A (ko) * 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
JP2019502728A (ja) 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ成熟阻害活性を有するルパンのアミン誘導体
WO2018044853A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Conpany Combinations and uses and treatments thereof
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
WO2019186342A1 (en) 2018-03-27 2019-10-03 Glaxosmithkline Intellectual Property (No.2) Limited Ionic liquid salts of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
EP3784349B1 (en) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
KR101909885B1 (ko) * 2018-05-25 2018-10-19 김예원 살리드로사이드 또는 베툴린을 이용한 뇌수막종 개선용 조성물
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
EP1292562A1 (en) 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Triterpenoid derivatives
NZ528270A (en) 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
AU2003296992A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
ATE384724T1 (de) 2002-12-13 2008-02-15 Smithkline Beecham Corp Cyclopropylverbindungen als ccr5 antagonisten
DE60324014D1 (de) 2002-12-13 2008-11-20 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
AU2003300902A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
JP2006512339A (ja) 2002-12-13 2006-04-13 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのインダン化合物
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20060019934A1 (en) 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
CN101142227A (zh) * 2004-11-12 2008-03-12 帕纳克斯医药公司 新颖的桦木醇衍生物、其制备和其用途
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP1869063A2 (en) 2005-03-29 2007-12-26 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006117666A2 (en) 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EP1986654A2 (en) 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
FI121468B (fi) 2006-06-07 2010-11-30 Valtion Teknillinen Betuliiniperäiset yhdisteet antimikrobisina aineina
UA97641C2 (xx) 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278)
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
AR063546A1 (es) * 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH.
JP2011508747A (ja) 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のｃ−２１ケトルパン誘導体、それらの調製および使用
EP2250185A4 (en) 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ2008723A3 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
MX351942B (es) 2008-12-11 2017-11-03 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2948132B1 (fr) 2009-07-20 2011-08-26 Inst Francais Textile & Habillement Association de produits cationiques et anioniques naturels comme liant pour support textile
US20120302534A1 (en) * 2010-02-11 2012-11-29 Daxin Gao Derivatives of betulin
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
WO2013020246A1 (en) * 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
AU2012352129B2 (en) 2011-12-14 2016-02-04 Glaxosmithkline Llc Propenoate derivatives of betulin
WO2013091144A1 (en) 2011-12-21 2013-06-27 Glaxosmithkline Llc Propenoate derivatives of betulin
CN104844679B (zh) * 2011-12-16 2017-03-01 葛兰素史克有限责任公司 白桦脂醇的衍生物
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
US20150209273A1 (en) 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
SG11201503807TA (en) 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물

Similar Documents

Publication Publication Date Title
JP2015501845A5 (enExample)
KR102583013B1 (ko) 항-hiv 화합물
KR102626210B1 (ko) N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
US10071985B2 (en) Therapeutic compounds
JP2022160589A (ja) Ｈｉｖを治療するためのトール様受容体の調節因子
EP3356355B1 (en) Compounds and combinations for the treatment of hiv
NZ716350A (en) Tricyclic benzoxaborole compounds and uses thereof
JP2020500866A5 (enExample)
HRP20240501T1 (hr) Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije
RU2018137389A (ru) Гетероциклические амиды, полезные в качестве модуляторов
ME02570B (me) Farmaceutska kompozicija koja sadrži ne-nukleozidni inhibitor reverzne transkriptaze
JP2013216697A5 (enExample)
JP2011173928A5 (enExample)
JP2019511542A5 (enExample)
JP2009525265A5 (enExample)
AU2009223064B8 (en) Use of 4'-Thio-2'-Deoxynucleosides as Anti Orthopoxvirus Agents
HRP20211895T1 (hr) Novi spojevi
AU2018239257B2 (en) HIV post-exposure prophylaxis
RU2018105343A (ru) Производные бетулина для предупреждения или лечения ВИЧ-инфекций
RU2018105352A (ru) Производные бетулина для предупреждения или лечения ВИЧ-инфекций
RU2018112958A (ru) Соединения с ингибирующей созревание ВИЧ активностью
US20220265689A1 (en) Hiv pre-exposure prophylaxis
EP4648770A1 (en) Compounds and method for treating hiv infection
HK40099977A (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
RU2020138670A (ru) Трициклические гетероциклические соединения, применяемые в качестве ингибиторов интегразы вич